Vaccination of healthcare workers with a bivalent dose against COVID-19 will be decentralized this week. For now it only applies Lima and Callao, Head of the National Institute of Health (INS) of MINSA, Victor Suarez, He informed that the plots would be distributed between Tuesday and Wednesday. He also said that the delay in taking the medicine to other areas was due to a logistical issue.
To date, Peru has received 552,960 doses of this new vaccine. It has started with healthcare professionals and will then continue with other at-risk groups, such as people above 60 years of age, those with co-morbidities, pregnant women and cancer patients. It is noteworthy that in some parts of the city this medicine was being given to those who did not work health sectorBut these facts will be only exceptions.
Along these lines, Suárez said that with the arrival of the following batches, more people will have access to the vaccine. Although the Ministry of Health (MINSA) initially announced that Peru would progressively receive a total of 13 million bivalent doses by March, the INS now indicates that this will be by July. A third arrival is planned for later this month, as there were two in November, and the lab still needs to confirm how many vaccines it will ship.
Meanwhile, when asked about the need for a fourth dose of known vaccines to reach the bivalent vaccine, a decision that has been questioned by experts, Suarez says that “Management protocols vary from country to country and vary over time, according to the availability of vaccines”, Right now, he said, there is only “a little too much” in the country.
dose of modern
Recently, Health Minister Rosa Gutierrez announced that incoming bivalent doses from laboratories Pfizer and Moderna, However, only the first one has authorization from the General Directorate of Medicines (Digemid). Getting permission from Digimid is the first step for the vaccine to reach the country and introduce it to the people. In this regard, the chief of INS told that the process is going on.
Similarly, he explained that the bivalent dosage of both brands are exchanges that have been made with the drug companies for the monovalent that was forthcoming; i.e, There will be no extra cost.